NYSE:HRC - Hill-Rom Stock Price, Forecast & News

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

Hill-Rom declared a quarterly dividend on Friday, November 8th. Shareholders of record on Monday, December 16th will be paid a dividend of $0.21 per share on Tuesday, December 31st. This represents a $0.84 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend is Friday, December 13th. View Hill-Rom's Dividend History.

Hill-Rom Holdings, Inc. (NYSE:HRC) issued its quarterly earnings data on Friday, January, 24th. The medical technology company reported $1.13 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.08 by $0.05. The medical technology company earned $685 million during the quarter, compared to analysts' expectations of $684.01 million. Hill-Rom had a net margin of 5.15% and a return on equity of 21.87%. The firm's revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.02 EPS. View Hill-Rom's Earnings History.

Hill-Rom is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for Hill-Rom.

Hill-Rom updated its FY20 earnings guidance on Friday, January, 24th. The company provided earnings per share guidance of $5.50-5.56 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.52. The company issued revenue guidance of +1-2% to $2.94-2.97 billion, compared to the consensus revenue estimate of $2.94 billion.

3 brokers have issued 12 month target prices for Hill-Rom's shares. Their forecasts range from $116.00 to $138.00. On average, they anticipate Hill-Rom's stock price to reach $127.50 in the next year. This suggests a possible upside of 23.4% from the stock's current price. View Analyst Price Targets for Hill-Rom.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.

Media stories about HRC stock have been trending neutral on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hill-Rom earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news articles about the medical technology company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Hill-Rom.

Hill-Rom saw a decrease in short interest in January. As of January 15th, there was short interest totalling 1,620,000 shares, a decrease of 12.4% from the December 31st total of 1,850,000 shares. Based on an average trading volume of 392,500 shares, the days-to-cover ratio is currently 4.1 days. Currently, 2.4% of the shares of the stock are short sold. View Hill-Rom's Current Options Chain.

Some companies that are related to Hill-Rom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), Paypal (PYPL), AK Steel (AKS), Endologix (ELGX), Walt Disney (DIS), Chipotle Mexican Grill (CMG), Micron Technology (MU), Mastercard (MA), AT&T (T) and Twilio (TWLO).

Hill-Rom's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (2.76%), State Street Corp (2.48%), Bank of New York Mellon Corp (1.63%), Bank of Montreal Can (1.58%), Geode Capital Management LLC (1.41%) and Bank of America Corp DE (1.24%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.

HRC stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Jennison Associates LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Credit Suisse AG, Lord Abbett & CO. LLC, AQR Capital Management LLC and State Street Corp. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.

HRC stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Renaissance Technologies LLC, Man Group plc, Panagora Asset Management Inc., AXA, State of New Jersey Common Pension Fund D, Acadian Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Hill-Rom.

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HRC stock can currently be purchased for approximately $103.29.

Hill-Rom has a market capitalization of $6.92 billion and generates $2.91 billion in revenue each year. The medical technology company earns $152.20 million in net income (profit) each year or $5.08 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.View Additional Information About Hill-Rom.

The official website for Hill-Rom is http://www.hill-rom.com/.

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]